Prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancer in a Japanese hospital-based population

Background The prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancers in the Japanese population have scarcely been investigated. Methods Immunohistochemistry for mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) was performed in formalin-fixed paraffin-embedded sections prepared from resected primary epithelial ovarian cancers in patients who underwent oophorectomy at our institution between April 2005 and September 2014. Genetic and/or epigenetic alterations of the mismatch repair genes were investigated in patients with loss of any mismatch repair proteins in the tumor. Results There were 305 patients with a median age of 54 years (range, 18-83 years). Loss of expression in the ovarian tumor of one or more mismatch repair proteins was observed in 3 of the 305 patients (0.98%): 2 patients MLH1/PMS2 loss and 1 patient showed MSH2/MSH6 loss. Genetic testing of these three patients failed to reveal any pathogenic germline mutations of MLH1 or MSH2. One patient with MLH1/PMS2 loss showed hypermethylation of the promoter region of MLH1. Somatic mutations were found in each of the alleles of MLH1 (c.545dupG and deletion of exons 2-19) in the other patient with MLH1/PMS2 loss. In the patient with MSH2/MSH6 loss, two somatic mutations were detected in MSH2 (c.229_230delAG and c.1861C>T), although we could not determine whether these mutations were biallelic or not. Conclusions The prevalence of defective mismatch repair epithelial ovarian cancer in the Japanese hospital-based population was extremely low. Molecular mechanism involved in such defective mismatch repair ovarian cancers seems to be epigenetic events through MLH1 promotor hypermethylation or somatically mutated mismatch repair genes without germline mismatch repair mutation.

[1]  D. Aoki,et al.  Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer , 2018, Journal of gynecologic oncology.

[2]  H. Tsuda,et al.  Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer , 2017, Oncotarget.

[3]  T. Sellers,et al.  Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens , 2017, Familial Cancer.

[4]  Y. Okazaki,et al.  Prevalence of Lynch syndrome and Lynch‐like syndrome among patients with colorectal cancer in a Japanese hospital‐based population , 2016, Japanese journal of clinical oncology.

[5]  T. Longacre,et al.  Lynch Syndrome: Female Genital Tract Cancer Diagnosis and Screening. , 2016, Surgical pathology clinics.

[6]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[7]  H. Hollema,et al.  Ovarian cancer in Lynch syndrome; a systematic review. , 2016, European journal of cancer.

[8]  J. Swensen,et al.  High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine , 2016, Familial Cancer.

[9]  P. Peltomäki.  Update on Lynch syndrome genomics , 2016, Familial Cancer.

[10]  E. Stoffel,et al.  Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. , 2015, World journal of gastroenterology.

[11]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[12]  E. Kuipers,et al.  Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.

[13]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[14]  R. Pai,et al.  Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer , 2014, The American journal of surgical pathology.

[15]  Rahul Bhagat,et al.  Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer. , 2014, Genomics.

[16]  H. Ahn,et al.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. , 2014, Gynecologic oncology.

[17]  Kieran Sheahan,et al.  Lynch Syndrome: An Updated Review , 2014, Genes.

[18]  T. Sellers,et al.  Risk Factors for Ovarian Cancers With and Without Microsatellite Instability , 2014, International Journal of Gynecologic Cancer.

[19]  I. Nagtegaal,et al.  Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. , 2014, Gastroenterology.

[20]  B. Clarke,et al.  Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  L. Braga,et al.  Evaluation of microsatellite instability in women with epithelial ovarian cancer. , 2012, Oncology letters.

[22]  A. Duval,et al.  Screening for Lynch Syndrome in Colorectal Cancer: Are We Doing Enough? , 2012, Annals of Surgical Oncology.

[23]  A. Karnezis,et al.  Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability , 2012, The American journal of surgical pathology.

[24]  Á. Carracedo,et al.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer , 2011, Gut.

[25]  M. Pino,et al.  Microsatellite instability in the management of colorectal cancer , 2011, Expert review of gastroenterology & hepatology.

[26]  A. de la Chapelle,et al.  Clinical relevance of microsatellite instability in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[28]  T. Sellers,et al.  Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology , 2008, Clinical Cancer Research.

[29]  T. Sellers,et al.  A review of the clinical relevance of mismatch‐repair deficiency in ovarian cancer , 2008, Cancer.

[30]  D. Rosen,et al.  Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma , 2006, Modern Pathology.

[31]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[32]  Å. Borg,et al.  The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. , 2006, Gynecologic oncology.

[33]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[34]  A. Sood,et al.  Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma , 2003, Cancer.

[35]  P. Maisonneuve,et al.  Carcinoma of the ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Møller,et al.  Familial endometrial cancer in female carriers of MSH6 germline mutations , 1999, Nature Genetics.

[38]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[39]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[40]  Aung Ko Win,et al.  Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency ( suspected Lynch syndrome ) , 2014 .

[41]  A. Duval,et al.  Lynch or not Lynch? Is that always a question? , 2012, Advances in cancer research.